RxDoctor Payments Data

Sandeep Mangalmurti, MD

Cardiovascular Disease · Schenectady, NYNPI 1083684781

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 76 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$214
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • Novartis$170
  • Merck$124
  • Johnson & Johnson$117
  • Scpharmaceuticals Inc.$96
  • plus $456 from 10 others

What the payments were for

  • Food & beverage$1,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,348 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$123,070
Medicare patients
527
Services billed
1,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban443$524,867
EntrestoSacubitril/Valsartan87$107,496
XareltoRivaroxaban30$45,266
JardianceEmpagliflozin17$20,636
BrilintaTicagrelor26$15,986
FarxigaDapagliflozin Propanediol19$14,836
Metoprolol Succinate378$7,497
Atorvastatin Calcium488$6,123
Ezetimibe134$3,896
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide154$2,721
Nifedipine ErNifedipine102$2,647
Valsartan33$1,930
Carvedilol233$1,815
Pitavastatin Calcium11$1,662
Lisinopril183$1,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$524,867443 claims
NovartisEntresto$170$107,49687 claims
Johnson & JohnsonXarelto$117$45,26630 claims
AstraZenecaBrilinta, Farxiga$61$30,82245 claims
Boehringer IngelheimJardiance$214$20,63617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →